

AMENDMENTS TO THE CLAIMS

Claims 1–2 (Canceled).

Claim 3 (Currently Amended): An immunogenic composition comprising as an immunogen a long synthetic or recombinant peptide ~~comprising epitopes contained within a~~ ~~consisting of MSP-3b peptide (SEQ ID No: 12)~~, a MSP-3c peptide (SEQ ID No: 13), or a MSP-3d peptide (SEQ ID No: 14) and combinations of said peptides.

Claim 4 (Previously Presented): A vaccine against malaria comprising the long synthetic or recombinant peptide of Claim 3 and a pharmaceutically acceptable carrier.

Claim 5 (Currently Amended): The immunogenic composition of claim 3, wherein said long synthetic or recombinant peptide further ~~consists of comprises the epitopes~~ ~~contained within~~ a MSP-3a peptide (SEQ ID No: 11).

Claim 6 (Previously Presented): The immunogenic composition of claim 3, which is formulated for subcutaneous injection.

Claim 7 (Currently Amended): The immunogenic composition ~~or the vaccine~~ of claim 6, comprising between 3 µg and 100 µg of a long synthetic peptide per injection dose.

Claim 8 (Currently Amended): The immunogenic composition of claim 3, further comprising Alum and/or Montanide ~~or an oil/surfactant adjuvant wherein the oil phase is~~

selected from a non-metabolizable mineral oil, a metabolizable mineral oil or a mixture of the two, as an adjuvant.

Claim 9 (Currently Amended): The vaccine of claim 4, wherein said pharmaceutically acceptable carrier comprises Alum and/or Montanide or an oil/surfactant adjuvant wherein the oil phase is selected from a non-metabolizable mineral oil, a metabolizable mineral oil or a mixture of the two.

Claims 10–24 (Canceled).

Claim 25 (Currently Amended): The vaccine of claim 4, wherein said long synthetic or recombinant peptide further ~~comprises the epitopes contained within~~ consists of SEQ ID No: 11.

Claim 26 (Previously Presented): The vaccine of claim 4, which is formulated for subcutaneous injection.

Claim 27 (Currently Amended): The ~~immunogenic composition or the~~ vaccine of claim 26, comprising between 3 µg and 100 µg of a long synthetic peptide per injection dose.

Claim 28 (New): An immunogenic composition comprising as an immunogen a long synthetic or recombinant peptide consisting of combinations of peptides of a MSP-3b peptide (SEQ ID No: 12), a MSP-3c peptide (SEQ ID No: 13) and a MSP-3d peptide (SEQ ID No: 14).

Claim 29 (New): A vaccine against malaria comprising a long synthetic or recombinant peptide consisting of combinations of peptides of a MSP-3b peptide (SEQ ID No: 12), a MSP-3c peptide (SEQ ID No: 13) and a MSP-3d peptide (SEQ ID No. 14) and a pharmaceutically acceptable carrier.

SUPPORT FOR THE AMENDMENTS

Claims 1, 2, and 10-24 have been canceled.

Claims 3, 5, 7-9, 25 and 27 have been amended.

Claims 28 and 29 have been added.

Claims 3, 5, 7-9, 25 and 27 have been amended to further clarify the present invention or to insert the generic terminology of the trademark Montanide® into the claims. Support for these amendments, as well as the addition of new Claims 28 and 29 are provided by the previously pending and originally filed claims. Further support for the generic terminology for “Montanide®” is provided by Hanly et al (see, Annex I).

Applicants have also amended the specification to indicate that “Montanide®” is a trademark and the generic terminology has been inserted for this trademark. Montanide® has also been capitalized wherever it appears. Also the status of the related applications appearing in the continuity data of the present application has been updated.

No new matter has been entered by the present amendment.